Isabella Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabella Pan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- David T. Rubin
University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL 60637
2 shared publications Noa Krugliak Cleveland
University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois
2 shared publicationsAlana Wichman
University of Chicago Medicine, 5841 S. Maryland Ave., MC 4076, Chicago, IL, 60637, USA
1 shared publicationAlex Gonsalves
University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois
1 shared publicationAnthony L. Tran
University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois
1 shared publication- Arthur S. Aelvoet
Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
1 shared publication
Latest Publications
- 1 January 2018
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (1) , 68-74
Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon
- 1 January 2018
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (1) , 68-74
Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon
- 24 August 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (10) , 2972-2976
Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis
Background Current guidelines emphasize vaccination for influenza and pneumococcus for IBD patients and the avoidance of live virus vaccines for those who are on immunosuppressive (ISS) therapy. Given the recent resurgence of measles and pertussis infections, we assessed the immune status of our IBD population in order to advise about these risks. Methods We prospectively collected measles and pertussis titers in our IBD patients from February 1–May 1, 2015. Immune status based on standard threshold values was determined: measles antibodies ≤0.8 antibody index (AI) = negative immunity, 0.9–1.1 AI = equivocal immunity and titers ≥1.2 AI = positive immunity. For pertussis immunity, anti-pertussis antibodies ≤5 IU/mL were considered negative immunity. Univariate analysis was performed to examine predictive factors including age, disease duration, and current medical therapies. Results A total of 122 patients’ titers were assessed (77 Crohn’s disease, 1 indeterminate colitis, and 45 ulcerative colitis). Sixteen (13.1 %) patients lacked detectable immunity to measles, and four (3 %) had equivocal immunity. Twelve (75 %) of the measles non-immune patients were on ISS therapy versus 65 (64 %) of 102 immune patients (OR 1.7, 95 % CI 0.5–5.9, p = 0.34). Out of 96 patients, 58 (60 %) were not immune to pertussis. Disease duration ≥10 years and age ≥50 were associated with significant lower measles titers. Conclusions A significant number of our IBD patients lack immunity to measles, and a majority of our IBD patients do not have detectable immunity to pertussis. Importantly, the majority of the measles non-immune patients are on ISS therapy and therefore unable to receive a booster.
- 24 August 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (10) , 2972-2976
Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis
Background Current guidelines emphasize vaccination for influenza and pneumococcus for IBD patients and the avoidance of live virus vaccines for those who are on immunosuppressive (ISS) therapy. Given the recent resurgence of measles and pertussis infections, we assessed the immune status of our IBD population in order to advise about these risks. Methods We prospectively collected measles and pertussis titers in our IBD patients from February 1–May 1, 2015. Immune status based on standard threshold values was determined: measles antibodies ≤0.8 antibody index (AI) = negative immunity, 0.9–1.1 AI = equivocal immunity and titers ≥1.2 AI = positive immunity. For pertussis immunity, anti-pertussis antibodies ≤5 IU/mL were considered negative immunity. Univariate analysis was performed to examine predictive factors including age, disease duration, and current medical therapies. Results A total of 122 patients’ titers were assessed (77 Crohn’s disease, 1 indeterminate colitis, and 45 ulcerative colitis). Sixteen (13.1 %) patients lacked detectable immunity to measles, and four (3 %) had equivocal immunity. Twelve (75 %) of the measles non-immune patients were on ISS therapy versus 65 (64 %) of 102 immune patients (OR 1.7, 95 % CI 0.5–5.9, p = 0.34). Out of 96 patients, 58 (60 %) were not immune to pertussis. Disease duration ≥10 years and age ≥50 were associated with significant lower measles titers. Conclusions A significant number of our IBD patients lack immunity to measles, and a majority of our IBD patients do not have detectable immunity to pertussis. Importantly, the majority of the measles non-immune patients are on ISS therapy and therefore unable to receive a booster.